Roger M. Leblanc received his B. S. in chemistry in 1964 from University Laval, Canada, and Ph. D. in physical chemistry in1968 from the same university. He was appointed as professor in 1994 and chair of Department of Chemistry at University of Miami from 1994 to 2002 and again from 2013 to 2021. He was also one of the three editors of Colloids and Surfaces B: Bio interfaces from 1998 to 2013. He has published 540 scientific articles in peer-reviewed journals. As a professor, he has supervised more than 100 M.S. and Ph.D. students.
Christopher R Bryant, Professor of University of Montreal & University of Guelph, Canada with 50 years of research experience in peri-urban agriculture (France, Canada and other countries) and 26 years research experience in adaptation of agriculture to climate change and variability as well as 30 years’ experience in community development. He was a Professor in Geography, the University of Waterloo for 20 years and Professor in Geography, University de Montreal for 24 years. He is also an Adjunct Professor in the School of Environmental Design and Rural Development at the University of Guelph, Canada.
Alexander Seifalian, Professor of Nanotechnology and Regenerative Medicine worked at the Royal Free Hospital and University College London for over 26 years, during this time he spent a period of time at Harvard Medical School looking at caused of cardiovascular diseases and a year at Johns Hopkins Medical School looking at treatment of liver. He published more than 647 peer-reviewed research papers, and registered 14 UK and International patents. He is currently CEO of NanoRegMed Ltd, working on the commercialisation of his research. During his career Prof Seifalian has led and managed many large projects with successful outcomes in terms of commercialisation and translation to patients. In 2007 he was awarded the top prize in the field for the development of nanomaterials and technologies for cardiovascular implants by Medical Future Innovation, and in 2009 he received a Business Innovation Award from UK Trade & Investment (UKTI). He was the European Life Science Awards’ Winner of Most Innovative New Product 2012 for the “synthetic trachea”. Prof Seifalian won the Nanosmat Prize in 2013 and in 2016 he received the Distinguish Research Award in recognition of his outstanding work in regenerative medicine from Heals Healthy Life Extension Society. His achievements include development of the world first synthetic trachea, lacrimal drainage conduit, and vascular bypass graft using nanocomposite materials, bioactive molecules and stem cell technology. He has over 15,000 media report from his achievement, include BBC, ITV, WSJ, CNN, and many more. Currently he is working on development and commercialisation of human organs using graphene based nanocomposite materials and stem cells technology.
Dr. Noreddin received his Ph.D. in pharmaceutical Sciences from the University of the Pacific, California and received research training as a visiting scholar at the Department of Medicine, Stanford University. He had postdoctoral fellowship (Pharmacokinetics and Pharmacodynamics of Antimicrobials), Department of Medical Microbiology, University of Manitoba followed by an American College of Clinical Pharmacy postdoctoral fellowship (Infectious Diseases). Dr. Noreddin’s research interest includes Pharmacoklinetic/Pharmacodynamic modeling of anti-infective and anti-cancer therapy, clinical simulation and Monte Carlo analysis and bacterial resistance in biofilm studies. Dr. Noreddin has outstanding records of scientific and academic accomplishments with multiple research funding, numerous publications in highly prestigious journals and various presentations in both national and international conferences. He served as a scientific reviewer for the NIH as well as other national and international research institutions
Mike Robinson, the founder Global Cannabinoid Research Center in Santa Barbara California has
extensive history in the world of Cannabis, Hemp, and more. As a patient he's a 3 time Cancer Survivor that's
used plant medicine to beat serious health issues. He's the founder of multiple entities in the US Cannabis market
and well known for R&D and formulations in the creation of investigative medicine and nutraceuticals. He's
an internationally published researcher with a primary focus on minor cannabinoids from Hemp. Robinson is the CEO
of a Nanotechnology Food & Beverage corporation that focuses on flavoring and preservation of foods, he's the owner
of multiple hemp/cannabis brands and the former Director of Consumer Affairs for the American Academy of Cannabinoid
Medicine. His skill set includes extensive legal knowledge coupled with cannabinoid medicine as a former Civil Rights Lobbyist.
Prior to that Robinson was a racecar driver and mortgage banker that was critically injured in a high speed auto racing wreck
2.5 decades ago that paralyzed him and caused severe epilepsy in which he uses cannabinoids to treat and recover from.
Director and founder of the Furnari Aesthetic ink Clinic
Dario Furnari is Ph.d. in Applied Biomedical Sciences in the neuroscience and traumatology and neuropharmacology sector
The lines of research on which he worked at the University of Catania, Department of Biotechnology and Biomedical Sciences, section of applied physiology and kinesiology and motion control, have been in the field of neuroscience, in particular in the role of beta-amyloid and glycoprotein F3 in the synaptic plasticity of hippocampal memory of mice and then in Alzheimer's disease; he dealt with behavior and various behavioral tests in mice; of electrophysiology of in vitro slices of hippocampus, stereotaxy and cannulation implantation, administration of drugs and animal welfare.